Boosting understanding of Lassa Fever virus epidemiology: Field testing a novel assay to identify past Lassa Fever virus infection in blood and oral fluids of survivors and unexposed controls in Sierra Leone.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
08
09
2020
accepted:
18
02
2021
revised:
12
04
2021
pubmed:
1
4
2021
medline:
6
7
2021
entrez:
31
3
2021
Statut:
epublish
Résumé
Despite identification 50 years ago, the true burden of Lassa Fever (LF) across Africa remains undefined for reasons including research focus on hospitalised patients, lack of validated field-feasible tools which reliably identify past infection, and the fact that all assays require blood samples making large-scale surveys difficult. Designated a priority pathogen of epidemic potential requiring urgent research by the World Health Organisation, a better understanding of LF sero-epidemiology is essential to developing and evaluating new interventions including vaccines. We describe the first field testing of a novel species-neutral Double Antigen Binding Assay (DABA) designed to detect antibodies to LF in plasma and oral fluid. Paired plasma and oral fluid were collected in Sierra Leone from survivors discharged from Kenema Government Hospital Lassa Fever Unit between 1980 and 2018, and from controls recruited in Freetown in 2019. Epidemiological sensitivity and specificity of the DABA measured against historical diagnosis in survivors and self-declared non-exposed controls was 81.7% (95% CI 70.7%- 89.9%) and 83.3% (72.7%- 91.1%) respectively in plasma, and 71.8% (60.0%- 81.9%) and 83.3% (72.7%- 91.1%) respectively in oral fluid. Antibodies were identified in people infected up to 15 years and, in one case, 40 years previously. Participants found oral fluid collection easy and painless with 80% happy to give an oral fluid sample regularly. Given the difficulties of assay validation in a resource-limited setting, including unexpected exposures and diagnostics of varying accuracy, the new assay performed well in both plasma and oral fluid. Sensitivity and specificity are expected to be higher when case/control ascertainment is more definitive and further work is planned to investigate this. Even at the performance levels achieved, the species-neutral DABA has the potential to facilitate the large-scale seroprevalence surveys needed to underpin essential developments in LF control, as well as support zoonotic investigations.
Sections du résumé
BACKGROUND
Despite identification 50 years ago, the true burden of Lassa Fever (LF) across Africa remains undefined for reasons including research focus on hospitalised patients, lack of validated field-feasible tools which reliably identify past infection, and the fact that all assays require blood samples making large-scale surveys difficult. Designated a priority pathogen of epidemic potential requiring urgent research by the World Health Organisation, a better understanding of LF sero-epidemiology is essential to developing and evaluating new interventions including vaccines. We describe the first field testing of a novel species-neutral Double Antigen Binding Assay (DABA) designed to detect antibodies to LF in plasma and oral fluid.
METHODOLOGY/PRINCIPAL FINDINGS
Paired plasma and oral fluid were collected in Sierra Leone from survivors discharged from Kenema Government Hospital Lassa Fever Unit between 1980 and 2018, and from controls recruited in Freetown in 2019. Epidemiological sensitivity and specificity of the DABA measured against historical diagnosis in survivors and self-declared non-exposed controls was 81.7% (95% CI 70.7%- 89.9%) and 83.3% (72.7%- 91.1%) respectively in plasma, and 71.8% (60.0%- 81.9%) and 83.3% (72.7%- 91.1%) respectively in oral fluid. Antibodies were identified in people infected up to 15 years and, in one case, 40 years previously. Participants found oral fluid collection easy and painless with 80% happy to give an oral fluid sample regularly.
CONCLUSIONS/SIGNIFICANCE
Given the difficulties of assay validation in a resource-limited setting, including unexpected exposures and diagnostics of varying accuracy, the new assay performed well in both plasma and oral fluid. Sensitivity and specificity are expected to be higher when case/control ascertainment is more definitive and further work is planned to investigate this. Even at the performance levels achieved, the species-neutral DABA has the potential to facilitate the large-scale seroprevalence surveys needed to underpin essential developments in LF control, as well as support zoonotic investigations.
Identifiants
pubmed: 33788861
doi: 10.1371/journal.pntd.0009255
pii: PNTD-D-20-01604
pmc: PMC8041174
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009255Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Infect Dis. 2019 Jul 19;19(1):647
pubmed: 31324229
Vector Borne Zoonotic Dis. 2014 Sep;14(9):665-74
pubmed: 25229705
PLoS One. 2019 Aug 2;14(8):e0215708
pubmed: 31374094
Lancet Infect Dis. 2017 Jun;17(6):645-653
pubmed: 28256310
J Infect Dis. 1987 Mar;155(3):437-44
pubmed: 3805771
BMJ. 2017 Jul 12;358:j2986
pubmed: 28701331
Open Forum Infect Dis. 2016 Feb 22;3(1):ofw031
pubmed: 27004234
BMJ Glob Health. 2019 Feb 7;4(Suppl 2):e001119
pubmed: 30899576
PLoS One. 2016 Apr 01;11(4):e0152854
pubmed: 27035916
NPJ Vaccines. 2018 Mar 20;3:11
pubmed: 29581897
Virol J. 2016 Oct 3;13(1):163
pubmed: 27716429
Contemp Clin Trials Commun. 2018 Jun 05;11:50-54
pubmed: 30003168
Pathog Glob Health. 2017 Sep;111(6):276-288
pubmed: 28875769
Oncotarget. 2016 May 10;7(19):27910-5
pubmed: 27058894
Pediatrics. 2016 Feb;137(2):e20152800
pubmed: 26812926
PLoS One. 2014 Aug 08;9(8):e100711
pubmed: 25105746
Bull World Health Organ. 2001;79(7):588-95
pubmed: 11477961
Transfusion. 2018 May;58(5):1289-1298
pubmed: 29572862
BMC Public Health. 2014 Apr 22;14:385
pubmed: 24755404
J Infect Dis. 2016 Oct 15;214(suppl 3):S203-S209
pubmed: 27521365
J Clin Microbiol. 2000 Jul;38(7):2670-7
pubmed: 10878062
PLoS Negl Trop Dis. 2014 Mar 20;8(3):e2748
pubmed: 24651047